Search Results
Your search for 3 matches 15052 pages
Showing 10701 - 10750No Survival Benefit for Cabozantinib Reported in Previously Treated Metastatic Castration-Resistant Prostate Cancer
Smith et al found no improvement in overall survival with cabozantinib (Cometriq) vs prednisone in patients with previously treated metastatic castration-resistant prostate cancer, in the phase III COMET-1 trial reported in the Journal of Clinical Oncology. Cabozantinib, which inhibits MET, VEGF...
Swiss Study Examines Cost-Effectiveness of Nivolumab vs Docetaxel in Advanced Nonsquamous NSCLC
Nivolumab, a checkpoint inhibitor approved for patients with squamous and nonsquamous non–small cell lung cancer (NSCLC) in 2015, is not cost-effective when compared to treatment with docetaxel, chemotherapy medication. However, a Swiss analysis showed the cost-effectiveness of nivolumab is...
Analysis Indicates Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage DLBCL
In an analysis of data from SWOG studies reported in the Journal of Clinical Oncology, Stephens et al found as continued risk of relapse among patients with limited-stage diffuse large B-cell lymphoma (DLBCL) irrespective of whether they received CHOP (cyclophosphamide, doxorubicin, vincristine,...
Early Results Find Pembrolizumab Active in Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
Findings in a classical Hodgkin lymphoma cohort in the phase Ib KEYNOTE-013 trial, reported by Armand et al in the Journal of Clinical Oncology, indicate that pembrolizumab (Keytruda) is active in patients with disease progressing on or after brentuximab vedotin (Adcetris) treatment. Study Details ...
PET/MRI: A One-Stop Imaging Test to Detect Prostate Cancer?
A University of Michigan study published by Piert et al in The Journal of Nuclear Medicine reported that the addition of molecular imaging based on F-18-choline positron-emission tomography (PET) improves the identification of significant prostate cancer over multiparametric prostate magnetic...
Juno Therapeutics to Resume JCAR015 Phase II ROCKET Trial After FDA Clinical Hold
Juno Therapeutics, Inc, announced on July 12, 2016, that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on the phase II clinical trial of JCAR015 (known as the ROCKET trial) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). Under the ...
Opportunistic Salpingectomy for Ovarian Cancer Prevention Adopted Without Adverse Surgical Outcomes
A surgical procedure recommended to reduce the future risk of ovarian cancer has been successfully implemented throughout Kaiser Permanente in Northern California without a change in surgical outcomes, according to research published by Garcia et al in Obstetrics & Gynecology. Previous...
Long-Term Benefit of Lenalidomide/Dexamethasone Reported in High-Risk Smoldering Multiple Myeloma
As reported by Mateos et al in The Lancet Oncology, long-term follow-up in the phase III QuiRedex trial indicates continued benefit of lenalidomide (Revlimid)/dexamethasone vs observation in preventing disease progression in patients with high-risk smoldering multiple myeloma. Study Details In...
First-Line Nivolumab Monotherapy Active in Advanced NSCLC
As part of the phase I CheckMate 012 study reported by Gettinger et al in the Journal of Clinical Oncology, nivolumab (Opdivo) monotherapy was found to be active as first-line treatment in advanced non–small cell lung cancer (NSCLC). The study is also examining first-line nivolumab plus...
First-Line Nivolumab Active in Combination With Platinum-Based Doublets in Advanced NSCLC
Nivolumab (Opdivo) was found to be active combined with platinum-based doublets as first-line treatment of advanced non–small cell lung cancer (NSCLC), as part of the phase I CheckMate 012 study reported by Rizvi et al in the Journal of Clinical Oncology. The study is also evaluating...
World GI 2016: Chemoradiotherapy After Surgery for Gastric Cancer Shows Similar Outcomes to Postoperative Chemotherapy
Postoperative treatment intensification with chemoradiotherapy does not achieve better outcomes compared to postoperative chemotherapy in patients with gastric cancer who have already undergone preoperative chemotherapy, according to phase III data presented by Verheij et al at the ESMO 18th World...
World GI 2016: Phase III RESORCE Study Data Show Regorafenib Improves Overall Survival in Previously Treated Patients With Unresectable Liver Cancer
Results from the phase III RESORCE trial show that regorafenib (Stivarga) tablets achieved a median overall survival improvement in patients with unresectable hepatocellular carcinoma (HCC) that progressed after treatment with sorafenib (Nexavar) tablets. The study, presented by Bruix et al during...
Updated Outcomes and Impact of Age in FIRST Trial in Multiple Myeloma
As reported by Hulin et al in the Journal of Clinical Oncology, the updated findings in the phase III FIRST trial continue to show improved progression-free and overall survival with continuous lenalidomide (Revlimid) plus low-dose dexamethasone (Rd) vs melphalan, prednisone, and thalidomide (MPT)...
Study Finds Incidence of Mutations in DNA-Repair Genes Significantly Higher in Men With Metastatic Prostate Cancer
The incidence of mutations in DNA-repair genes was significantly higher among men with metastatic prostate cancer than among men with localized disease (11.8% vs 4.6%), according to a study by Pritchard et al reported in The New England Journal of Medicine. In addition, the frequency ...
Mixed Results With Hypofractionated vs Conventional Radiotherapy for Localized Prostate Cancer
Investigators of two European phase III trials have reached different conclusions on whether hypofractionated radiotherapy should replace conventional radiotherapy as a new standard of treatment in localized prostate cancer. The CHHiP trial findings favoring hypofractionation were reported by David ...
Ann G. Schwartz, PhD, MPH, Elected to ILCCO Steering Committee
Ann G. Schwartz, PhD, MPH, Deputy Center Director and Executive Vice President for Research and Academic Affairs at the Barbara Ann Karmanos Cancer Institute and Professor and Associate Chair in the Department of Oncology at Wayne State University School of Medicine, was recently elected to a...
Erika P. Hamilton, MD, Named Director of Breast and Gynecologic Cancer Research
Sarah Cannon has announced the promotion of Erika P. Hamilton, MD, to Director of the institution’s Breast and Gynecologic Cancer Research Program. Over the past 3 years, Dr. Hamilton has been instrumental in the growth and success of the program. “Erika has quickly become a recognized thought...
2016 Oncology Meetings
JULY Pan Pacific Lymphoma ConferenceJuly 18-22 • Koloa, Hawaii For more information: www.unmc.edu/cce/catalog/clinicmed/panpacificlymphoma/index.html UK Breast Cancer Research SymposiumJuly 22-23 London, United Kingdom For more information: http://breastcancerconference.org Mayo Clinic Oncology...
Prevention Needed to Stem Global Rise in Human Papillomavirus–Related Anal Cancer
The incidence rate of human papillomavirus (HPV)-related anal cancer and its precursor lesion, anal intraepithelial neoplasia, is rising in the United States and globally. Although 5-year survival rates in localized disease are generally favorable, survival in metastatic disease remains poor,...
A Concerned Physician Reflects on Today’s Doctor-Patient Relationship
Doctoring isn’t what it used to be. Like many other professions, it has gone through a multitude of changes ostensibly to improve efficiencies and lower costs. The digital age has reshaped clinical practice from the front office to the exam room. And with the advent of electronic health records...
Managing Upper Extremity Dysfunction in Breast Cancer Survivors
With an increased number of breast cancer survivors and patients with metastatic disease living longer, it is imperative for oncology care providers to manage issues of new and chronic upper extremity dysfunction as a result of the malignancy itself or its treatment. As one of my patients...
Greatest Benefit of Adjuvant Exemestane in Premenopausal Women at Higher Risk of Breast Cancer Recurrence
In an analysis of the SOFT and TEXT trials reported in the Journal of Clinical Oncology, Meredith M. Regan, ScD, of Dana-Farber Cancer Institute, and colleagues found that the greatest benefit of adjuvant exemestane in reducing breast cancer recurrence was among women with the greatest risk of...
Complexities in the Diagnosis and Management of Amyloidosis
Question 1: What is the next best step for this patient? Correct Answer: C. Determination of amyloid subtype. Expert Perspective Amyloidosis encompasses a heterogeneous group of diseases bound by the characteristic deposition of amyloid fibrils in soft tissues and bone marrow, and it could be...
Complexities in the Diagnosis and Management of Amyloidosis
Case Study A 70-year-old man is referred to your clinic for a consultation. Recently, a diagnosis of IgG monoclonal gammopathy of undetermined significance (MGUS) was established. Medical history is significant for essential hypertension, type II diabetes mellitus, hyperlipidemia, and atrial...
Routine Prophylactic vs Deferred Radiotherapy for Procedure-Tract Metastases in Malignant Pleural Mesothelioma
Prophylactic radiotherapy after surgery and large-bore pleural procedures did not result in significant reduction in the incidence of procedure-tract metastases in malignant pleural mesothelioma, according to the UK phase III SMART trial reported by Clive et al in The Lancet Oncology. Study...
Comparison of Chemotherapy Regimens After Negative Interim PET-CT in Advanced Hodgkin Lymphoma
In a phase III trial reported in The New England Journal of Medicine, Johnson et al found similar efficacy with continued ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy vs omission of bleomycin (AVD) after negative interim PET-CT (positron-emission tomography–computed...
Cancer Research Grant Opportunities for Early-Career and Junior Faculty Researchers
The Conquer Cancer Foundation of ASCO (CCF) is currently accepting applications for the 2017 Young Investigator Award (YIA) and Career Development Award (CDA). Young Investigator Award (YIA) A 1-year grant totaling $50,000, the YIA provides research funding to promising physicians to support the...
Recent Staff Announcements at Fox Chase Cancer Center
Philip A. Pancari, MD, has joined the Department of Hematology/Oncology at Fox Chase Cancer Center, providing additional physician support for the Fox Chase Cancer Center–Temple University Hospital Bone Marrow Transplant (BMT) Program. “Having worked at Fox Chase for the past 3 years as a...
What’s Driving the Rising Rates of Colorectal Cancer in Young Adults?
The study statistics are alarming—and perplexing. According to an analysis of data from the Surveillance, Epidemiology, and End Results (SEER) colorectal cancer registry, colon cancer incidence among young adults aged 20 to 34 is expected to increase 90% by 2030, and the incidence of rectosigmoid...
Computed Tomography–Based Lean Body Mass Calculations May Improve Accuracy of PET for Patients With Cancer
Patients with cancer often experience significant fluctuations in weight and lean body mass. Neglecting to account for these changes can prevent clinicians from obtaining precise data from molecular imaging, but a new method of measuring lean body mass takes changes in individual body composition...
FDG–PET Evaluates Immunotherapy for Non–Small Cell Lung Cancer
Researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) presented study findings on a means of evaluating an immunotherapy for non–small cell lung cancer (NSCLC).1 Due to NSCLC’s relative insensitivity to chemotherapy, the use of immunotherapies,...
Atezolizumab Promising in Cisplatin-Ineligible Metastatic Bladder Cancer
Atezolizumab (Tecentriq), an anti–programmed cell death ligand 1 (PD-L1) inhibitor, achieved durable responses as first-line treatment in cisplatin-ineligible patients with metastatic urothelial carcinoma in a primary analysis of a phase II trial. These data represent an unmet need, because...
New Standard of Care Emerges for Anaplastic Glioma Without 1p/19q Codeletion
Adjuvant temozolomide, after radiotherapy, improves overall survival in patients with grade 3 anaplastic glioma without 1p/19q codeletion, according to a phase III EORTC (European Organization for Research and Treatment of Cancer) study presented at the 2016 ASCO Annual Meeting.1 “We were...
CAR T-Cell Dose Refinement May Reduce Cytokine-Release Syndrome in Patients With Advanced Acute Lymphoblastic Leukemia
Chimeric antigen receptor (CAR) T-cell therapy has been effective in adults and children with advanced acute lymphoblastic leukemia (ALL), but along with efficacy, the treatment can stimulate cytokine-release syndrome, which can be deadly if it goes unrecognized and untreated. Adjusting the dose...
Expert Point of View: Elizabeth Mittendorf, MD, PhD
The discussant of these studies was Elizabeth Mittendorf, MD, PhD, Associate Professor of Breast Surgical Oncology at the University of Texas MD Anderson Cancer Center, Houston. Dr. Mittendorf noted that approximately 3% of U.S. breast cancer patients present with de novo stage IV disease. For...
Mixed Results With Resection of Primary Tumor in Stage IV Breast Cancer
For de novo stage IV breast cancer, does resection of the primary tumor improve outcomes? Two studies presented at the 2016 ASCO Annual Meeting reached different conclusions. A prospective randomized study conducted in Turkey concluded there is a survival benefit at 5 years,1 whereas a U.S....
Expert Point of View: Stephen K.L. Chia, MD
Stephen K.L. Chia, MD, of the British Columbia Cancer Agency, Vancouver, discussed two of these neoadjuvant breast cancer studies at the ASCO Annual Meeting. In the current landscape for neoadjuvant therapy in HER2-positive disease, said Dr. Chia, the NeoSphere, TRYPHAENA, KRISTINE, and I-SPY 2...
Pertuzumab-Containing Regimens Compared for Neoadjuvant Treatment in Early Breast Cancer
In patients with HER2-positive early breast cancer, pathologic complete response rates after neoadjuvant therapy were higher with docetaxel plus carboplatin plus trastuzumab (Herceptin) plus pertuzumab (Perjeta), or TCH+P, than with ado-trastuzumab emtansine (Kadcyla) plus pertuzumab, or T-DM1+P,...
Analysis of Cerebrospinal Fluid for D-2-Hydroxyglutarate May Detect Malignant Brain Tumors Nonsurgically
When a brain tumor is suspected, its presence is usually confirmed by anatomic imaging such as computed tomography (CT) or magnetic resonance imaging (MRI). But through imaging, not much about the tumor molecularly can be learned. Surgery and a biopsy are necessary to get a glimpse of the cancer...
The Age of the Atomic Hematologists/Oncologists
Every longstanding culture has ages: The Minoans were followed by the Mycenaeans and, later, the Hellenistic peoples. And so it is with hematology/oncology. A descriptive age dominated predominately by histopathologists was followed by an age of experimentalists. Development of the atomic bombs...
Assessment of Fitness, Function, and Quality of Life Essential in Treatment of Older Patients With CLL
Significant progress has been made in the past 2 decades in the care of patients with chronic lymphocytic leukemia (CLL). Recently, the therapeutic armamentarium has expanded for such patients with the introduction of new targeted agents. CLL is predominantly a disease of the elderly, with a...
Improved Survival Reported With Prostate Radiation Therapy Plus Androgen-Deprivation Therapy in Metastatic Prostate Cancer
The addition of prostate external-beam radiation therapy to androgen-deprivation therapy was associated with prolonged overall survival in men with newly diagnosed metastatic prostate cancer, according to a National Cancer Database analysis reported by Rusthoven et al in the Journal of Clinical...
Study Finds Regorafenib Increases Progression-Free Survival in Advanced Gastric Cancer
The multikinase inhibitor regorafenib (Stivarga) prolonged progression-free survival vs placebo in patients with previously treated advanced gastric carcinoma, in a phase II trial reported in the Journal of Clinical Oncology by Pavlakis et al. A regional difference in treatment effect was observed. ...
Combination of Nivolumab and Ipilimumab Moves Forward in NSCLC
How best to combine new immunotherapies is a burning question in oncology. A new study in the CheckMate series suggests that nivolumab (Opdivo) and ipilimumab (Yervoy) can be safely and effectively combined as first-line treatment of advanced non–small cell lung cancer (NSCLC),1 but further study...
No Advantage With Cyclophosphamide/Methotrexate Maintenance in Hormone Receptor–Negative Early Breast Cancer, but Subgroup May Benefit
Low-dose oral cyclophosphamide plus methotrexate maintenance therapy yielded no disease-free survival benefit in women with hormone receptor–negative early breast cancer, according to the phase III International Breast Cancer Study Group (IBCSG) 22-00 trial. Some evidence of benefit was...
Tasquinimod Improves Radiographic PFS but Not OS in Metastatic Castration-Resistant Prostate Cancer
In a phase III trial reported in the Journal of Clinical Oncology, Sternberg et al found that tasquinimod, an oral therapy targeting components of the tumor microenvironment, increased radiographic progression-free survival but not overall survival vs placebo in men with chemotherapy-naive...
Study Finds Adding Olaratumab to Doxorubicin Improves Survival in Advanced Soft-Tissue Sarcoma
The addition of olaratumab, an anti–platelet-derived growth factor receptor alpha (anti–PDGFRα) antibody, to doxorubicin resulted in prolonged progression-free and overall survival in the phase II evaluation of patients with advanced soft-tissue sarcoma, according to findings...
French Phase III Trial Shows No Benefit of Adding Zoledronate to Chemotherapy and Surgery in Osteosarcoma
In the French phase III OS2006 trial reported by Piperno-Neumann et al in The Lancet Oncology, the addition of zoledronate to chemotherapy and surgery provided no event-free survival benefit in the treatment of patients with newly diagnosed high-grade osteosarcoma. Study Details In the open-label ...
Adding Obinutuzumab to Bendamustine Improves Progression-Free Survival in Rituximab-Refractory NHL
In the phase III GADOLIN trial reported in The Lancet Oncology, Sehn et al found that adding the anti-CD20 antibody obinutuzumab (Gazyva) to bendamustine (Bendeka, Treanda) increased progression-free survival in patients with rituximab-refractory indolent non-Hodgkin lymphoma (NHL). Outcomes in...
FDA Approves Sofosbuvir/Velpatasvir for Treatment of Chronic Hepatitis C Virus Infection
On June 28, the U.S. Food and Drug Administration (FDA) approved a fixed-dose combination of sofosbuvir, 400 mg, plus velpatasvir, 100 mg (Epclusa) to treat adult patients with chronic hepatitis C virus (HCV) either with or without cirrhosis. For patients with moderate to severe cirrhosis...
